Prevention of Cytokine Release Syndrome in Chimeric Antigen Receptor T-cell Therapy
DOI:
https://doi.org/10.54097/fd6pgk68Keywords:
CAR T-cell therapy, cytokine release syndrome, proinflammatory cytokines.Abstract
One of the most powerful forms of cancer immunotherapies is chimeric antigen receptor (CAR) T-cell therapy. Despite being fairly recent in terms of its development and approval, CAR T-cells show great potential as a treatment, since they can efficiently recognize and destroy tumor cells. However, due to the various toxicities associated with this treatment option, CAR T-cell therapy is usually advised as a last resort. The most prominent toxicity of CAR T-cell therapy is the onset of immunotoxicity, which includes Cytokine Release Syndrome (CRS). This review will focus on the recent definition of CRS in general, the mechanisms of CRS progression, how tumor cell pyroptosis via. CAR T-cell therapy can trigger CRS, and the strategies to prevent CRS that have shown efficiency in the application of CAR T-cell patients. By the end, this article will highlight the combination of inhibitors of CRS to improve tumor therapy in the future.
Downloads
References
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021b). Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Journal of Experimental & Clinical Cancer Research, 40(1).
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2017b). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 9(6), 7204–7218.
Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E., Melenhorst, J. J., Qian, W., Liang, A., & Han, W. (2020). The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 5(1).
Miao, E. A., Rajan, J. V., & Aderem, A. (2011). Caspase-1-induced pyroptotic cell death. Immunological Reviews, 243(1), 206–214.
Kang, S., & Kishimoto, T. (2021). Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Experimental and Molecular Medicine, 53(7), 1116–1123.
Barrett, D. A., Singh, N., Hofmann, T. J., Gershenson, Z., & Grupp, S. A. (2016b). Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function. Blood, 128(22), 654.
Liu, Y., Fang, Y., Chen, X., Wang, Z., Liang, X., Zhang, T., Liu, M., Zhou, N., Lv, J., Tang, K., Xie, J., Gao, Y., Cheng, F., Zhou, Y., Zhang, Z., Hu, Y., Zhang, X., Gao, Q., Zhang, Y., & Huang, B. (2020). Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Science Immunology, 5(43).
Teachey, D. T. (2020b). Spotlight on tocilizumab in the treatment of car-T-cell-induced cytokine release syndrome: clinical evidence to date. DOAJ (DOAJ: Directory of Open Access Journals), 16, 705–714. Journal of Neuro-Oncology, 23(1), 112–121.
Siegler, E. L., & Kenderian, S. S. (2020). Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: Insights into mechanisms and novel therapies. Frontiers in Immunology, 11.
Kang, L., Tang, X., Zhang, J., Li, M., Xu, N., Qi, W., Tan, J., Lou, X., Yu, Z., Sun, J., Wang, Z., Dai, H., Chen, J., Lin, G., Wu, D., & Yu, L. (2020b). Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. Experimental Hematology & Oncology, 9(1).
Li, M., Xue, S., Tang, X., Xu, J., Chen, S., Han, Y., Qiu, H., Miao, M., Xu, N., Tan, J., Kang, L., Yu, Z., Lou, X., Xu, Y., Chen, J., Yan, Z., Feng, W., Wu, D., & Yu, L. (2022). The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Scientific Reports, 12(1).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
